Top SEC Enforcer Walks Rather Than Play Politics
Enforce the law? In this economy?
Enforce the law? In this economy?
An NYU Stern report links private equity in healthcare to worse outcomes and higher bankruptcy risk, calling for reforms and stronger oversight.
Drawing on more than a decade of data, the report equips law firms and corporate legal teams with actionable insights to better assess risk, refine strategy, and anticipate outcomes in today’s evolving workplace disputes.
Our president is wasting billions he doesn’t have to fight a war he didn’t have to fight.
And that's just for THIS month.
Trump responds to only one thing: the market.
Experts say Hims & Hers’ acquisition of Eucalyptus positions the company for global expansion and revenue diversification amid U.S. GLP-1 regulatory challenges.
Put away the guesswork—Lexis® Verdict & Settlement Analyzer helps legal professionals assess case potential with confidence by using data-driven insights from the industry’s largest collection of verdicts and settlements.
Let's cut through the confusion and focus on what actually matters for your planning.
Digital health is entering a more mature phase in 2026 as consolidation accelerates through targeted M&A, driven by the need for scale, artificial intelligence and pressure from payers, investors say.
Saint Laurent, Miu Miu, and Cos maintained their top-three positions as fashion's hottest brands for another quarter.
Depositions by Filevine help with scheduling, tracking goals, and trial prep.
Across all industries, the total number of companies on track to go public could make this week the most active for IPOs since 2021. Despite the partial government shutdown, there are paths biotechs can pursue to the public markets.
As shakedowns go, it's pretty shakey.
Old associations are resurfacing, raising uncomfortable questions for Wall Street's most powerful bank.
Cancer drugs are always popular biotech investments, but autoimmune disease also figures prominently in the startup financings announced during the annual J.P. Morgan Healthcare Conference this year.
The top SASC Democrat stopped short of supporting Trump's executive order, as a few defense firms said they're on board, at least publicly.